FLT3 and acute myeloid leukemia: This fits with clinical data from the SORAML trial,57 which reported that FLT3 mutation status alone was not indicative of increased event-free survival with sorafenib treatment in conjunction with chemotherapy, likely due to the ability of sorafenib to target multiple signaling pathways and the signaling differences present in different subtypes of AML.